Good afternoon. Thank you for standing by. Welcome to the CTI BioPharma's Vonjo FDA approval conference call. During today's presentation, all parties will be in a listen-only mode. After the speaker presentation, there will be a question- and- answer session. To ask a question during the session, you will need to press star one on your telephone. This conference is being recorded today, March 1st, 2022. I'd like to turn the conference over to Dr. Adam Craig, CEO and President of CTI BioPharma. Please go ahead. Thank you, and welcome to this morning's conference call to discuss the FDA approval of Vonjo pacritinib. Joining me today are David Kirske, Chief Financial Officer, Bruce Seeley, Chief Operating Officer, and Jim Fong, our newly promoted Chief Commercial Officer. Following formal remarks, the conference will be open for questions. Before we begin, please note that during this call we will be making forward-looking statements based on current expectations. Such statements are within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the types of statements identified as forward-looking in our 2020 annual report on Form 10-K and our subsequent periodic reports filed with the SEC, which are available on our website in the investors section. These forward-looking statements represent our views only as of the date of this call, are not guarantees of future performance, and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements, including many that are beyond our control. For a further description of the risks and uncertainties that could cause actual results to differ, as well as risks related to our business generally, please see our periodic reports filed with the SEC. Today marks an exciting day for CTI and for patients with cytopenic myelofibrosis, patients who've been waiting too long for a new and effective treatment option. Yesterday, we announced the accelerated FDA approval of Vonjo pacritinib for the treatment of adults with myelofibrosis with a platelet count below 50 × 10^9 per liter. The approval was based on the phase III PERSIST-2 trial, a study that enrolled myelofibrosis patients with platelet counts less than or equal to 100 × 10^9 per liter, making it the only randomized controlled study specifically designed around the cytopenic myelofibrosis population, that is, patients with thrombocytopenia and anemia. Our commercial team is recruited, trained, and ready to launch. With the receipt of a $60 million payment from DRI Healthcare on approval, our launch is fully funded with drug expected to be available to patients within the next 10 days. Finally, with a compelling product label that will allow us to be competitive both now and in the future, we are well-positioned to enter an addressable market of up to $3 billion. That includes a large number of patients with cytopenias. Myelofibrosis or MF is a cancer of the bone marrow that results in scarring of the marrow tissue, which often leads to cytopenias, particularly thrombocytopenia, anemia, and can lead to weakness, fatigue, enlarged spleen, and liver. With an estimated addressable market of up to $3 billion, the opportunities for Vonjo are substantial. In the U.S., there are approximately 21,000 people with MF. Two-thirds of these patients have cytopenias resulting from either disease progression or commonly from the toxicity of other approved therapies. Severe thrombocytopenia, defined as a blood platelet count below 50 × 10^9, occurs in 1/3 of the overall MF population and has a particularly poor prognosis with an overall survival of just 15 months. For many years, Jakafi or ruxolitinib has been the mainstay of MF care. However, despite its extensive use, the majority of treated patients are receiving low subtherapeutic doses of Jakafi, predominantly due to myelosuppression from the drug. As this slide shows in the left-hand panel, in a recent real-world study of 2,700 patients receiving Jakafi, 63% of patients treated were receiving low doses. This is despite the product label for Jakafi stating that the use of low-dose Jakafi should be limited as, quote, "The 5 mg twice-daily dose has not shown responses." It is therefore not surprising to learn that healthcare providers are generally not satisfied with low-dose Jakafi, as illustrated in the right-hand panel of this slide. I will now move on to describe the unique profile of Vonjo and the details of the FDA approval. Vonjo has a profile that differentiates it from other JAK inhibitors. First, it is a novel JAK2 and IRAK1 inhibitor, the latter being an emerging target in the treatment of MF. Second, unlike Jakafi, Vonjo does not inhibit JAK1, an important differentiator as JAK1 inhibition is believed to be a cause of drug-related myelosuppression. Vonjo was granted accelerated approval by the FDA for the treatment of adults with intermediate or high risk primary or secondary myelofibrosis with a platelet count below 50 × 10^9. The NDA supporting the Vonjo approval was reviewed under priority review by the FDA. The product label, which will soon be available on our corporate website and at www.vonjo.com, is based on the data from the phase III PERSIST-2 study and includes safety data on patients with platelet counts less than or equal to 100 × 10^9. Importantly, unlike other JAK inhibitors, the Vonjo product label does not include a black box safety warning, nor was a REMS program required by the FDA. The adverse event data in the product label includes all patients from the PERSIST-2 trial who were treated with Vonjo 200 mg twice daily in patients with platelet counts up to and including 100 × 10^9 per liter. In this population, nearly half the patients had a platelet count of below 50 × 10^9, the equivalent of at least Grade 3 thrombocytopenia, and the median baseline hemoglobin was 9.5 g/dL. The most common adverse reactions were diarrhea, thrombocytopenia, nausea, anemia, and peripheral edema. It is important to note that similar to other JAK inhibitors used to treat MF, the prescribing information for Vonjo also contains what FDA has described as class labeling for JAK inhibitors. That is, warning language for major cardiac events, thrombosis, secondary malignancies, and risk of infections. These warnings were not a result of any particular finding during the FDA's review of the Vonjo NDA, but rather reflect safety concerns that have arisen when other JAK inhibitors are used to treat rheumatoid arthritis, as announced by the FDA in their safety bulletin in September of last year. As part of the accelerated approval of Vonjo, CTI is required to complete the ongoing PACIFICA study as a post-marketing commitment. PACIFICA is a multinational randomized controlled phase III study of Vonjo for the treatment of primary and secondary MF patients with severe thrombocytopenia. That is a platelet count below 50 × 10^9 per liter. Patients are randomized in a 2:1 ratio to receive either Vonjo 200 mg twice daily or physician's choice, which includes the option of low-dose Jakafi. From the FDA request that was made concurrent with granting accelerated approval, the PACIFICA study protocol is in the process of being amended to include co-primary endpoints of spleen volume reduction and the reduction of total symptom score. To allow for the co-primary endpoints, the study sample size has been increased to 399 patients. With this sample, we estimate that the spleen volume endpoint will have greater than a 99% power to detect at least a 16% difference between the treatment arms. With the TSS endpoint having greater than 85% power to detect at least a 13% difference between the treatment arms. In addition, at the FDA's request, the previously described interim analysis of SVR at 168 patients will no longer take place. As such, final data is now expected mid-2025. Before handing over to Jim to discuss the commercial launch of Vonjo, I'd like to spend a few minutes describing some of the compelling data from the PERSIST-2 trial in more detail. We believe the findings from PERSIST-2 are very important, as it is the only randomized controlled trial to specifically study the cytopenic MF population in all lines of therapy. PERSIST-2 is the quintessential study of cytopenic MF, which enrolled patients with platelet counts less than or equal to 100 × 10^9 per liter, including frontline patients who were treatment naive and second-line patients who had received prior JAK2 inhibitor therapy. Treatment with Vonjo was compared to best available therapy or BAT, which included watch and wait, and the only approved JAK inhibitor at the time, Jakafi. The co-primary endpoints of the study were reduction in spleen volume and TSS at week 24. In the study population with severe thrombocytopenia, that is platelet count below 50 × 10^9 per liter, who were treated at the approved dose of Vonjo 200 mg twice a day, 29% of patients achieved at least a 35% reduction in spleen volume with Vonjo, compared to 3.1% with BAT. In the same population treated with Vonjo 200 mg twice a day, 26% of patients achieved at least a 50% reduction in their total symptom score with Vonjo, compared to 9% with BAT. Important clinical effects on hematologic parameters in PERSIST-2 are shown in the next two slides. For patients who received on-study transfusions with one or more units of red blood cells, the transfusion requirements at weeks 12 and 24 were lower on the 200 mg twice-daily Vonjo arm compared to BAT, as shown in the left-hand panel. For patients with a baseline hemoglobin below 10 g/dL, the proportion of patients with clinical improvement in hemoglobin at week 24, defined as an increase of greater than or equal to 2 g/dL or red blood cell transfusion independence for greater than or equal to eight weeks, was greater with Vonjo twice daily at 25% compared to BAT at 12%, as shown on the right-hand panel. Blood count stabilization is also an important goal of therapy in cytopenic myelofibrosis. In patients with transfusion independence at baseline, treatment with Vonjo, 200 mg twice daily, resulted in hematologic stability for both platelet count and hemoglobin levels. With that, I will now pass the call over to our new Chief Commercial Officer, Jim Fong. Jim has been at CTI for nearly 13 years, most recently as Senior Vice President of Commercial, and has over 30 years of global commercial experience and product launch experience. Jim, congratulations on your promotion. I'm excited to have you lead the Vonjo launch. Thank you, Adam. CTI believes that Vonjo has the potential to serve a critical unmet medical need in myelofibrosis. Now, with its approval by the FDA, our commercial organization is fully prepared and highly motivated to partner with the myelofibrosis patient and physician community to bring this important therapy to patients in need of a meaningful new treatment option. As Adam mentioned earlier, patients with cytopenic myelofibrosis are estimated to make up to 2/3 of patients with MF, with severe thrombocytopenic patients accounting for a third of all patients. Thrombocytopenia can either occur as a result of disease or commonly as a result of toxicity from the other currently approved treatments. Inspired by the needs of these patients, our commercial team has been preparing for an approval and launch of Vonjo since the latter part of 2020. Following yesterday's announcement, we expect to make Vonjo available to patients within 10 days of approval. We have completed the hiring, onboarding, and training of our commercial team, a team comprising of 59 key account managers and seven regional business directors, all of whom are highly seasoned oncology sales professionals with decades of experience launching in hematology, oncology, rare diseases, and importantly, proficiency operating in the COVID environment. Our sales force will be dedicated to rapidly educating healthcare practitioners in both the community and academic settings. The MF market is highly concentrated with 4,700 U.S. prescribers treating approximately 80% of potential Vonjo patients, the majority of which are in the community setting. Our market research indicates that there is a high demand for new treatments that address the well-defined unmet needs of the cytopenic MF population. I'm pleased to report that our market access team has been in place for several months and has been actively engaging with payers, pharmacy benefit managers, group purchasing organizations, and distributors to ensure rapid coverage decisions and availability. Payers do recognize the unmet need addressed by Vonjo, and as such, we expect rapid coverage to the label. CTI Access, our patient support program, is up and running, and as I will discuss in more detail shortly. Lastly, yesterday, my medical affairs colleagues submitted our data to the NCCN for inclusion in their guidelines for the treatment of myelofibrosis. As we launch Vonjo, we have three main objectives that will enable us to build a strong foundation for success. First, we need to build awareness among MF treaters as to the clinical significance and prevalence of cytopenic disease, the specific challenges these patients face, and the limitations of existing therapies to adequately treat these patients. Furthermore, we will ensure the recognition of the unique clinical profile of Vonjo and how it addresses the challenges of cytopenic MF patients. Through its unique mechanism of action, targeting JAK2 and IRAK1 without inhibiting JAK1, Vonjo has demonstrated the ability to address not only splenomegaly and symptoms, but also beneficially address anemia, transfusion burden, and platelet counts. Because of its unique profile and ease of administration at full dose, we expect Vonjo will be a valuable new treatment option in both the academic and community setting. Secondly, we need to drive adoption and utilization within our top accounts and HCPs. In recognition of the challenge due to COVID-19, we have adapted our launch preparations by investing in a mix of both in-person and virtual promotional resources to support our experienced field team while also leveraging peer-to-peer programs, digital marketing, and medical conferences to ensure maximal HCP coverage and appropriate education. Third, we need to ensure optimal patient access to Vonjo. As previously mentioned, we now have launched CTI Access, our comprehensive patient support program. CTI Access, staffed by highly skilled oncology case managers with deep experience in access and reimbursement, will offer patients high-touch support throughout the reimbursement process. CTI Access will provide robust financial assistance programs for eligible patients, including copay assistance, rapid start, and coverage interruption programs, and where appropriate, a program that will provide Vonjo at no cost to eligible patients who do not have insurance or whose insurance does not cover Vonjo. Finally, moving on to pricing. The initial wholesale acquisition cost, or WAC, for a 30-day supply of Vonjo will be $19,500 per month. This price reflects Vonjo's role as an important new therapeutic option, serving a previously unmet medical need based on impressive data we have seen from the phase III PERSIST-2 study. We anticipate that discounts to government entities and channel partners will impact the gross to net price that CTI will receive for Vonjo, with our gross to net being in line with our peer companies, with some variability quarter- to- quarter as we gain experience in the marketplace. In conclusion, Vonjo has the potential to be the best-in-class JAK inhibitor for cytopenic myelofibrosis. It is the only drug to have demonstrated meaningful clinical benefit in both front-line and second-line cytopenic patients in a randomized clinical trial. Vonjo has a manageable safety profile and can be given at full dose in the cytopenic setting with minimal dose modifications, thereby optimizing the clinical benefit in this population. Importantly, both platelet count stabilization and clinical improvement in hemoglobin has been demonstrated with Vonjo. I'd now like to turn the call back over to Adam. Thank you, Jim, and once again, congratulations on your promotion. Before closing, I'd like to thank the large number of people who have contributed to the successful approval of Vonjo. First, the team at the FDA for their collaboration during the review process and for their willingness to enter into a dialogue about the significant unmet medical need of patients with myelofibrosis. Second, the patients, caregivers, families, and healthcare professionals who participated in our clinical trial. Without their significant contribution and sacrifice, we would not be here today. Third, my team at CTI for their hard work and dedication on the Vonjo program and for their passion in advancing CTI's mission, the delivery of new therapies to blood-related cancer patients with unmet medical needs. To conclude, the FDA approval of Vonjo brings to the market the only JAK2 inhibitor to demonstrate meaningful clinical benefit in patients with cytopenic myelofibrosis in a randomized clinical trial, with improvements in spleen size and other parameters and a predictable and manageable safety profile. Vonjo is simple to administer and can be given at full dose in the cytopenic setting. With a comprehensive patient support program in place, we aim to provide Vonjo to all appropriate patients, regardless of their ability to pay. CTI is now a fully integrated commercial company. Our finances are strong, and we are funded through launch. We have a compelling product label that will allow us to be competitive both now and in the future. Our commercial team is experienced, and the market opportunity for Vonjo is substantial. From today, we are excited to be able to offer new therapy to cytopenic myelofibrosis patients who've been waiting a long time for safe and effective treatment option. Thank you. With that, Victor, we can now open the call to Q&A. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, just press the pound key. Once again, that's star one for questions. Our first question will come from the line of Reni Benjamin from JMP Securities. Your line is open. Hey, good morning, guys. Thanks for taking the questions. Of course, congratulations on this approval. A real testament, you know, Adam, to you and the rest of the management team there. Congrats on that. Maybe just a couple of quick questions. One regarding the label, were there any, you know, surprises, either positive or negative that, you know, you feel is worth noting? You know, specifically, when I look at, you know, the indications of usage and the use for platelet counts below 50 × 10^9 per liter versus some of the comments that you made regarding the PERSIST-2 study focusing on, you know, platelet counts below 100. I'd love to maybe kinda get your thoughts as to maybe why that didn't make it into the label and how that might impact the initial commercial process. Good morning, Ren. Thank you for your questions. First of all, the discussion with the FDA was always around the most pressing unmet medical need. Early discussions with the agency that started over two years ago were always about patients with platelet counts less than 50. That was the priority. You ask us what was surprising about the label. The FDA did see the value in including a broader safety data set in the label. As you will see, the safety data in this data set is actually for patients with platelet counts less than 100. It's all the patients who received 200 mg of Vonjo on the trial. That was something we were very happy with because it shows it enables treating physicians to see the safety across a broader range of platelet counts. The other thing that probably wasn't a surprise, but I think it's important to note because a lot of people are expecting it, we don't have a black box warning for bleeding or cardiac events. There are many people who thought that would be the case. We did not propose a black box warning when we presented our initial draft label over nearly a year ago to the FDA, and the FDA agreed with that decision, and at no time were we discussing a black box warning. I think that's a great outcome for us, and it also obviously differentiates us from the other JAK inhibitors. Got it. When you think about, you know, commercial, you know, as we, you know, the drug will be available within the next 10 days. Can you talk a little bit about, you know, either requests from healthcare providers? Is there some sort of a bolus of centers that might have participated in the clinical trials that are already, you know, kind of talking to you and wanting it? Trying to get an idea as to the, if there's any sort of pent-up demand and what your sales force is kind of facing. Yeah. We're not going to make specific comments, Ren, about pent-up demand, but I'll comment first, and I'll let Jim comment after me. We've had, over the last couple of months, a lot of interest from physicians saying they have patients when the drug will be available. We have had a fantastic last sort of 12, 24 hours where a lot of those physicians have contacted us. We do expect a strong start to the launch because there is demand there. I'll let Jim comment more. Yeah. Hi, good morning, Ren. In addition, our medical affairs team has been out, interfacing with the KOLs over the last, you know, 8 months. In those interactions, you know, certainly they have heard the KOLs talking about keeping patients, you know, stable until pacritinib gets approved. There's no doubt. We can't give guidance on it, but there's no doubt there's a lot of interest and there are patients waiting for this therapy. Thank you, Jim. Terrific. Then just one final one for me if you don't mind. You know, we had always talked about, I think waiting for the PACIFICA study results before tackling, let's say, the rest of the world, Europe in particular. Kinda given the trial changes that have taken place and then when the final data might come out, is there any sort of a change in your thinking as to how you might tackle the rest of the world opportunity? Thank you. Thank you, Renny. Our thinking hasn't changed. We always plan to, on the approval of Vonjo, the U.S. sites would shut down for PACIFICA, and we will continue the trial in the rest of the world. We've made a lot of effort over the last six to 12 months to increase our footprint across the world to more countries and more sites. We're very well prepared to continue PACIFICA. The only change really is in the timeline, because the FDA requested co-primaries for TSS and SVR. We have increased the sample size to maintain strong power of the study, and in the FDA's words, "The powering that will enable a win for both TSS and SVR." That means with the additional patients, it will take a little bit longer, and that's why we're giving conservative guidance of mid-2025 for the data. Terrific. Thanks again and congratulations. appreciate it. Thank you, Ren. Next question. Our next question comes from the line of Bert Hazlett from BTIG. You may begin. Thanks. It's Bert Hazlett here, and thank you for taking the questions. For goodness sakes, my congratulations as well to your team, Adam, and the efforts you've made with the regulatory authorities. Very impressive. My questions have to do with actually the red blood cell transfusions. You know, obviously in the label there is a focus on platelets, but how important do you think the data will be on its impact on red blood cell transfusions as you move forward in the marketplace? Thank you, Bert, for your question. The answer is very important, and I'll hand over to Jim to give you the perspective from a commercial viewpoint. Yeah. Hey, Bert. Good morning. As we talk about the definition of cytopenic myelofibrosis, Ben, is patients with less than 100,000 platelet counts, and with or without, you know, plus or minus anemia. Those two hematologic issues go hand in hand together, so they often occur, like in the PERSIST-2 trial, we saw that 60% of the patients with less than 100,000 platelet counts also had anemia and transfusion dependence. It is very important because, and that's the whole definition of cytopenic myelofibrosis, because they do go hand in hand. Thanks. Looking forward to the penetration there. Then just as we think about the different patient groups, how do you think about, is there ability to address the patients with platelets between 50,000 and 100,000? Obviously the label specifically addresses those less than 50,000, but I'm interested in whether or not you might think you think there might be consideration in that other group. Yeah, Bert. As you know, I just want to reiterate, our team will be promoting with the labeled indication, which is less than 50,000 platelet counts across all lines of therapy. Having said that, physicians, as you know, healthcare professionals are allowed to use their best medical judgment in how they prescribe therapies, particularly in oncology. Given the level of dissatisfaction and frustration we have heard through market research and advisory boards, we would not be surprised if there is spontaneous utilization of pacritinib in that population, particularly given the fact that the PERSIST-2 study that was the pivotal study that included that population. Terrific. Thanks. That's all for me, and congratulations again. Thank you, Bert. Our next question will come from the line of Ben Burnett from Stifel. You may begin. Hey, good morning. I'll add to my congrats. Absolutely great news. I wanna just go back to a comment that I think was mentioned in the prepared remarks. I think you mentioned something about Vonjo being included in the treatment guidelines for MF. I guess you have a sense for the timing of that, and how important is that to reach community physicians? Thank you, Ben, for your question. It's very important. About 60% of our prescribers will be in the community, about 40% in the academic setting. To date, these physicians have struggled to treat patients with low platelet counts. Now they have the option, it's very important that we communicate how the drug can be used. The team submitted our request for the data to be included in the NCCN guidelines to the NCCN last night. Typically, it takes anywhere from two to four weeks for the change in guidelines. That's the timeline we're working on. As soon as we have those, they'll become a very, very important part of community practice. Excellent. Okay, that's super helpful. One other quick question, just in terms of some of the pricing dynamics. Is there any other additional color you can provide on the discount expectations? And then also just timing for securing broad formulary access. We're not going to offer any details of discounting on this call. Formularies, Jim? Yes. For the Medicare lives, we expect to have 90% coverage in the first six months, and we expect to have at least 50% coverage of the commercial lives in the first six months. Within 12 months, we expect to have 90% coverage across both commercial and Medicare lives, which will be similar to what we've seen in other myelofibrosis treatments. Okay. That's great. I appreciate it, and congrats again. Thank you, Ben. Our next question will come from the line of Thomas Flaten from Lake Street Capital. Your line is open. Yeah, thanks, guys, and Mike, congrats as well. Is this gonna be available broadly in retail pharmacy, or is it gonna be specialty? Jim? Yes, it's gonna be available via specialty pharmacy and specialty distributors. How many of those are you using? Is it single source or? Thomas, we're not going to provide that level of detail today, but thank you for your question. Yep. Could you walk us through perhaps the logic or the rationale that the FDA used to redesign, so to speak, the PACIFICA study? I'm curious why they recommended that change. It was a very straightforward discussion we had very close to the approval. They wanted, as part of the accelerated approval, we need to demonstrate clinical benefit in a post-marketing trial, and they wanted us to make sure that we had a win both for SVR and TSS. When they made the request for co-primaries for the two endpoints, we looked at the powering of the study, and we went back to the FDA, and we proposed a larger study that had both SVR and TSS as co-primaries. It was satisfactory, and the FDA accepted the design. The study is very well powered to be a success, and that's the sole purpose of this trial is to demonstrate clinical benefit, to confirm clinical benefit following the accelerated approval. I think we're very well positioned to do that. Just one final one, if I may. With respect to maybe broadly broadening utilization to the cytopenic myelofibrosis from the more restrictive label, is there gonna be promotion kind of in the consistent with label approach, or is it gonna be more of a medical science liaison-driven approach, more from a data perspective? Or can you give us some color on how you're hoping to talk to docs about that? Well, the medical science liaison will continue to talk about the scientific message and the data, have data discussions around Vonjo. For the commercial team, we will be using a combination of the label and data consistent with label in our promotional efforts. Great. Much appreciated. Thank you. Thank you, Thomas. Our next question comes from the line of Gil Blum from Needham. Your line is open. Good morning. Again, let me add my congratulations as well. Just a couple of quick ones from us. Can you remind us of the patient dynamics with regards to development of thrombocytopenia? From what I remember, patients who go on drug eventually, you know, go on ruxolitinib, eventually all progress to being thrombocytopenic. How long does that usually take? Yes. We spent a lot of time looking into this. Jim? Yeah, Gil. Typically, it depends on the dose that they're on, when you look at the COMFORT trial, at their normal starting dose of 15 and 20 mg BID, you see about a 40% drop in platelet count that occurs within the first 8 weeks. It occurs pretty rapidly. Now as you go down in the doses, you start to see that taper off a bit. Again, you'll see that typically in the first eight weeks of treatment. Okay. That's very helpful. Maybe another quick one. Do payers currently provide coverage for low-dose ruxolitinib? Yes, they do. We have seen that essentially the payers are only looking to ensure that the patients are symptomatic in terms of their coverage of myelofibrosis treatments. All right. That's all from us. Again, congratulations, and I look forward to seeing the drug progress in the market. Thank you, Gil. I appreciate it. Next question will come from the line of Boris Peaker from Cowen. You may begin. Thank you, and I'd like to add my congratulations as well. Thank you, Boris. Great. My question is, I'm just curious, how well do we know the dynamics of Jakafi, specifically number of patients that maybe over the last six months to a year discontinued therapy due to thrombocytopenia or perhaps are being kept on the lowest dose of Jakafi just to manage a thrombocytopenia? And how can you find and reach those patients? Yeah. As Adam mentioned in the previous slides, during his talk, we have seen with the prescription audit that approximately 28%-30% of all patients on ruxolitinib are indeed taking the 5 mg, their lowest dose. If you think about it's quite a significant number if you calculate approximately 8,000 patients are on ruxolitinib at any given time, so there's well over 2,000 patients that are taking the 5 mg dose. How easy is it to find these patients? I'm just curious from a practical standpoint. Would this be kind of the lowest hanging fruit patients in terms of adoption? I'm just trying to think how to model that out. Yeah. Yeah. You know, our team, our sales force, has been out there profiling accounts in the past 4 or 5 months, and as such, a lot of the questions we've been asking are where are these patients? What doses do you have them on? We have a good idea of which practices have the majority of these low platelet count patients and patients who are taking low dose ruxolitinib. Great. Thank you for taking my question. Thank you. I'm not showing any further questions in the queue. I'd like to turn the call back over to Adam for any closing remarks. Thank you, Victor. Thank you for joining us on today's call and for your interest and continued support as CTI launches its first commercial product in the U.S. We are eager to deliver this important therapy to MF patients who've been waiting a long time for an effective and safe new treatment. We look forward to providing updates on the progress of our commercial launch as the year progresses. Thank you and goodbye. This concludes today's conference call. Thank you for participating. You may now disconnect. Everyone, have a great day.